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Abstract 
The excitatory, ionotropic glutamatergic AMPA receptor is the most common 
membrane-bound receptor in the central nervous system. AMPARs and the 
NMDA receptors are central to synaptic plasticity, memory, and mechanisms of 
neurodegeneration. The AMPAR is an obligate heterotetramer, composed of 
subunits GluA1-4. Subunit permutation determines ion conductance, trafficking 
and other functional characteristics. Few available antibodies are subunit-specific, 
disabling researchers from accurately visualizing differential AMPAR subunit 
distribution in the nervous system. This study sought to visualize a novel 
monoclonal GluA1/2/3 antibody with functional avidity for three of four receptor 
subunits and to characterize the ultrastructural localization of these receptors using 
confocal and electron microscopy.  
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Introduction 
 
AMPA Receptors 
 
 The identification of the AMPA-type ionotropic glutamate receptor as the primary 
regulator of fast excitatory transmission in the CNS constitutes one of the major 
achievements of modern neuroscience. These ubiquitous receptors are critical for 
synaptic plasticity, mediating memory-associated changes in dendritic morphology, 
signaling the expression of neurotrophins, and are implicated in many neurological 
disorders. 1 
 AMPA receptors (AMPARs) were named for the artificial 
selective agonist and glutamate analogue !-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid by Tage Honore and colleagues 
at the Royal Danish School of Pharmacy in Copenhagen, and 
published in 1982 in the Journal of Neurochemistry. 2  
 
Receptor Structure and Mechanics 
 AMPARs are obligate heterotetramers, composed of subunits GluA1-4, 3 with 
each subunit possessing a binding pocket for the neurotransmitter glutamate. 4 From 1989 
to 1992, the genes encoding the four subunits (GRIA1-4) were identified. 5 Different 
combinations of subunits determine the pharmacological, functional and trafficking 
characteristics of the channel. 6 Diversity can also come in the form of post-translational 
modifications and splice variants (such as the Arg607 Q/R residue). 7   
 
 
Figure 1: AMPAR Heterotetramer and Generic Subunit Structure. 8 
AMPA 
 2 
 
 
Fig 2: Electron micrograph of GluA2 tetramer showing dual N-terminal domains, ligand binding domains, 
and the transmembrane domain. 9  
 
 Receptor subunits are composed of an N-terminal extracellular domain (NTD) 
with an intermediate ligand binding domain (LBD), four transmembrane domains (TMD), 
and an intracellular C-terminal tail that interacts with a multitude of scaffolding proteins 
involved in structure and signaling at the post-synaptic density. These include NSF, AP-2, 
PICK1, GRIP, ABP, KIF5, PKC, PKA, SAP97, PSD95, and a family of Transmembrane 
AMPAR Regulatory Proteins (TARPs) such as stargazin. 10, 11 12 
 
 
Fig 3: Proteins that associate with the C-terminus of the AMPAR. 11 
 
 In adult excitatory hippocampal neurons, most AMPARs are composed of GluA1-
2 or GluA2-3 complexes. 13 All AMPARs are ligand-gated cation channels, allowing 
sodium in and potassium ions out, tending toward an equilibrium potential of 0 mV 
(about halfway between ENa+ and EK+). GluA2, however, is calcium impermeable. And 
GluA2 trumps GluA1 in a heterotetramer. The majority of AMPARs in the hippocampus 
(approximately 80%), however, possess GluA2 and are therefore calcium impermeable. 14 
 3 
As a result, AMPARs are “dependent” upon NMDA-mediated calcium influx in the 
LTP/LTD response (see the section on Synaptic Plasticity below).  
 In 1998, Eric Gouaux’s laboratory reported the first structural assessment of the 
isolated ligand-binding domain. They identified the N-terminal extracellular structure as 
a “clamshell” that is closed by the binding of two glutamate molecules, leading to the 
opening of the ion pore in a scissor-like motion. 15 Models of activation and 
desensitization states have been developed using computational x-ray crystallography.  
 
 
Figure 4: Preliminary activity state models of the AMPAR. Desensitization is characterized by reduced 
response after prolonged exposure to agonist. This process is mediated by separation of the upper lobes of 
the LBD dimer. 16 
 
Receptor Trafficking 
 
Biogenesis 
 
 AMPAR subunits are mostly synthesized in the somatic endoplasmic reticulum, 
modified and assembled into tetramers in the Golgi apparatus and finally inserted into the 
membrane where they laterally diffuse in and around the dendrite. AMPARs are 
synthesized in response to neural activity, a process mediated by the metabotropic GluRs 
1 and 5. 17 
 AMPARs are also synthesized within dendrites. The mRNA is packaged and 
transported via microtubules in response to glutamatergic stimuli. Translational outposts 
in the dendrites consist of polyribosomes and golgi structures. Interestingly, D1/D5 
dopaminergic agonism is also capable of augmenting AMPAR synthesis and eliciting a 
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heightened frequency of spontaneous miniature excitatory postsynaptic currents 
(mEPSCs) in the hippocampus. 18  
 
Synaptic Targeting 
 
 Long-term potentiation, depression, and the attendant memory and learning are 
mediated by rates of synthesis, membrane transport, and endocytosis of AMPA receptors.  
Vesicular trafficking from the Golgi involves dyneins and kinesins, small molecular 
motors that move cargo along microtubules. 19 Trafficking from the soma to the dendrites 
is mediated by the TARP family of chaperone-like proteins. 
 
 
Figure 5: TARP-mediated AMPAR trafficking from endoplasmic reticulum to dendrite, followed by 
PSD95 binding. 11  
 
 A complex of GluR2, the PSD protein GRIP1, and kinesin can be 
immunoprecipitated from brain lysates, and the expression of nonfunctional versions of 
kinesin decreases synaptic abundance of AMPARs. 20 Within the dendritic spines, actin 
and myosin have been implicated in clathrin-dependent endocytosis and local AMPAR 
trafficking. 21 
 Stargazin, a calcium channel gamma-subunit homolog, plays a major role in 
several points of the AMPAR secretory process. 22 Originally identified as the mutant 
gene in the Stargazer mouse, which is afflicted with cerebellar ataxia and epilepsy, it has 
since been shown to promote transport of AMPARs to the cell surface. Stargazer mouse 
cerebellar granule cells consequently show very low AMPAR levels at the synapse. 23  
 Post-synaptic density protein 95 (PSD 95) is a structural protein critical to 
AMPAR stability. Stargazin is complexed with both AMPARs and PSD95, which 
anchors the group to the post synaptic density. Overexpression of PSD95 results in 
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increased AMPAR-mediated synaptic currents, 24 and knockdown results in decreased 
AMPARs at the synapse. 25 
 
Exocytosis and Endocytosis 
 
 AMPARs have a metabolic half-life of approximately 30 hours. 26 Explaining 
their synaptic dynamics, especially in light of their role in long-term memory, is a critical 
area of research. For example, it remains controversial whether AMPARs are primarily 
inserted into the synapse directly or into the adjacent extrasynaptic membrane and then 
laterally diffuse to the synapse.  
 AMPAR insertion is dependent upon subunit composition. Insertion of long-tailed 
C-terminus AMPARs GluA1/4 occurs slowly under basal conditions and is stimulated by 
NDMA activation and neural activity. In contrast, receptors containing GluA2/3 tend to 
be constitutively trafficked to the synapse under basal conditions and are not dependent 
upon neural activity. 27  
 AMPA receptors are held in intracellular reserve pools and are fused with the 
membrane as necessary. The administration of tetanus toxin cleaves SNAREs and blocks 
AMPAR insertion at the synapse. 28 N-ethylmaleimide-sensitive fusion protein (NSF) has 
been shown to bind with the C terminus of the GluA2 subunit, regulating rapid 
exocytosis. AMPARs in the reserve pool complex with PICK1, a protein that is thought 
to stabilize the reserve pool. When NSF binds with PICK1, the former dissociates from 
AMPARs and enables them to fuse with the synapse. 29 
 Endocytosis of AMPARs is similar to that of G-protein coupled receptors 
(GPCRs) because both processes feature clathrin-coated pits and require dynamin. 30 
After being internalized, AMPARs are engulfed by early endosomes and sent either to a 
specialized recycling endosome compartment that allows quick reinsertion to the surface 
or to late endosomes and ultimately lysosomes for degradation. 31 
 The immediate early gene CPG2 mediates basal and activity-regulated AMPAR 
internalization and localizes to the endocytic zone. CPG2 knockdown inhibited AMPAR 
and NMDAR endocytosis. 32 Another immediate early gene, Arc, is induced by neural 
activity and directly implicated in cognition and long-term memory. Arc mRNA is tightly 
regulated and translated at activated synapses. Arc regulates AMPAR trafficking via 
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interactions with the endocytic proteins dynamin and endophilin. 33 Finally, Tumor 
Necrosis Factor Alpha (TNF-!) augments AMPAR insertion. 34 
 
 
Figure 6: Schematic of AMPAR associated trafficking proteins. 1 
 
 Recycling and degradation may be coordinated, at least in part, by ubiquitination 
signals and the ubiquitin-proteasome system (UPS). Monoubiquitination has been shown 
in C. elegans to signal endocytosis, whereas polyubiquitination leads to proteasome 
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degradation. 35 In mammalian neurons, targeted mutation of the ubiquitin peptide at 
lysine 48 prevented AMPA-induced receptor internalization. 36 The role of ubiquitination 
in AMPAR recycling remains an active area of study.  
 
Synaptic Plasticity 
 
 Changes in synaptic strength are believed to underlie memory storage. 37 Hebbian 
Learning postulates “neurons that fire together wire together,” and that neurons sensitize 
or desensitize in response to repeated stimuli. In the terms of Neural Network Theory, 
memory is encoded in the pattern of synaptic strength or “weights” distributed across the 
probability space of possible connections. Likewise, forgetting is the loss or decay of this 
pattern of synaptic weights.  
 Long-term potentiation (LTP) and long-term depression (LTD) are the two most 
studied cellular models of synaptic plasticity. 38 AMPARs are the metaphorical “currency” 
of LTP and LTD, and the NMDA receptor can be understood as the cashier – transacting 
in AMPARs under various stimulus conditions. 39 Long-term memory formation 
putatively involves cyclic AMP response element binding protein (CREB) and Mitogen-
activated protein kinases (MAPK). 40 
 
 
 
Figure 7: A) LTP Recording Setup, B) Augmented AMPAR current and number of AMPARs at the 
synapse in response to high frequency vs. low frequency stimulation. 7 
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Long-Term Potentiation 
 
 Long-term potentiation can be defined as the long lasting enhancement of signal 
transmission that results from synchronous stimulation. The phenomenon was first 
demonstrated in the rabbit hippocampus by Terje Lømo and Tim Bliss in 1966, who 
stimulated Schaffer collateral (pyramidal CA3) neurons and recorded from CA1 
pyramidal cells. The effect has been shown to last for weeks in vivo, and to correlate with 
performance on spatial memory tasks. 41 LTP also involves other regions of the brain 
such as the limbic system and cortex. 42 
 Inducing LTP experimentally involves stimulating the presynaptic neuron with a 
high frequency (typically 100 Hz for one second) tetanus, resulting in an excitatory post-
synaptic potential. The postsynaptic neuron will be sensitized and more likely to respond 
with a higher amplitude output for an extended period of time. A single AMPAR-
mediated excitatory post-synaptic potential (EPSP) has a rise time-to-peak of 
approximately 2–5 ms and a mean duration of 30 ms. If stimulated one hundred times a 
second, the AMPAR will attempt to open every 10 ms (including the refractory period), 
the EPSC will increase, and EPSPs will sum resulting in a moderate local depolarization, 
triggering NMDARs and initiating a sequence that leads to increased synaptic weighting.  
 AMPARs are mostly found as GluA2-containing heterotetramers, which are 
impermeable to calcium. For LTP to occur, NMDA (named for the selective agonist N-
methyl-D-aspartate) receptors must be activated. NMDARs are dual-ligand (glutamate 
and D-serine or glycine) and voltage-gated due to magnesium ion blockade at resting 
potential (-70 mV). AMPARs depolarize the membrane potential enough to dislodge the 
Mg2+ ion (about 0 mV) and enable the NMDAR Ca2+ current to flow inward.  
 In short, the role of the AMPAR is to initiate a local membrane depolarization 
sufficient to revoke the Mg2+ blockade, leading to the activation of the more “powerful” 
NMDARs, which, in turn, instigate a cascade that results in the regulation of AMPAR 
membrane insertion. Many excitatory synapses are actually thought to be 
postsynaptically 'silent', possessing functional NMDARs but lacking AMPARs. The 
acquisition of AMPARs at silent synapses may also be important in synaptic plasticity 
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and neural development. 43 
 Kinase phosphorylation is crucial in the regulation of neural function, like in most 
cell types. 44 AMPAR phosphorylation is also an integral part of LTP. 45 A substantial rise 
in calcium concentration within the dendritic spine initiates LTP by activating kinases. 
Low calcium influx activates phosphatases leading to long-term depression (LTD).  
 AMPARs are phosphorylated by Calcium/calmodulin-dependent kinase II 
(CaMKII), which was discovered in the lab of Paul Greengard in 1978, another 
monumental discovery in the molecular neuroscience of memory and learning. 46 
CaMKIIA isoform knockout mice demonstrate a low frequency of LTP and fail to form 
persistent, stable place cells in the hippocampus. 47 CaMKII itself is autophosphorylated 
in the presence of NMDAR-mediated calcium influx. CaMKII does not appear to be 
necessary for recruiting AMPARs to the synapse but phosphorylation Ser831 of GluA1 
does indeed augment ion conductance. 48, 49, 50  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Phorphorylation of AMPARs influences cation conductance, as 
well as playing a role in dendritic spine trafficking and membrane 
insertion. 45 
 10 
 Protein Kinase A (PKA) phosphorylation of GluA1 at Ser845 is also critical to 
LTP.  Intracellular perfusion of PKA into HEK 293 cells transfected with GluA1 led to a 
40% potentiation of whole cell glutamate current peak amplitude, 51 likely by increasing 
open-channel probability. 52 This potentiation effect was lost when Ser845 was mutated to 
alanine. Site-directed mutagenesis and pharmacological studies indicate that this 
phosphorylation is necessary but not sufficient for GluA1 membrane insertion during 
LTP. 53 LTP was diminished in mice with mutated knock-in Ser381 and Ser845 sites that 
resist phosphorylation. 54 Protein Kinase C (PKC) has also been shown to phosphorylate 
Ser818 of GluA1, a modification that is implicated in synaptic trafficking during LTP. 55 
 
Long-Term Depression 
 
 As downtrodden as this molecular process sounds, it is actually critical to synaptic 
plasticity and rather something to be upbeat about. LTD is the means by which a 
postsynaptic neuron becomes desensitized to input from the presynaptic neuron, 
putatively by means of NMDAR-dependent AMPA receptor endocytosis. 56,57 The state is 
induced by low frequency stimulus (1 Hz) over an extended period of time. Most studies 
take place in hippocampal sections in vitro, so it remains a challenge determining how 
the mechanism actually works in vivo. Heynen et al., however, have demonstrated that 
hippocampal AMPAR postsynaptic membrane surface expression increased with LTP 
and decreased with LTD in vivo. 58 
 Insulin plays a role in LTD, by activating phosphatidylinositol 3-kinase (PI3K) 
and protein kinase B (PKB) via an NMDAR-dependent mechanism, 59 as well as by a 
distinct AMPAR sorting pathway to specialized endosomes. 60 LTD is dependent upon 
calcium influx and the activation of the phosphatase calcineurin. 61 For hippocampal LTD, 
Ser845, the PKA site on GluA1, is dephosphorylated. Mice with this site mutated exhibit 
deficits of LTD and NMDAR-induced AMPAR internalization. 62 In the cerebellum, 
chemical activation of PKC was sufficient to phosphorylate Ser880 of GluA2 and induce 
LTD and AMPAR internalization. 63 Interestingly, PKC does not appear to mediate the 
phosphorylation of Ser880 in the hippocampus, indicating that this requirement is 
satisfied by other kinases. 64  
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Homeostatic Scaling 
 
 Chronic excitation or inhibition leads to compensatory mechanisms in cultured 
neurons. Raising activity by blocking inhibitory synaptic transmission markedly 
decreased the synaptic AMPAR population and reduced the EPSC. This also applied to 
NMDARs. 65 Likewise, the chronic administration of AMPAR antagonists for hours to 
days at a time increased the synaptic AMPAR population. 66  
 Both TNF-! and the immediate early gene Arc have been implicated in this 
homeostatic process. By administering tetrodotoxin (TTX), a voltage-gated Na+ channel 
blocker, glutamate release can be suppressed. This low level of glutamate causes glia to 
release TNF-!, which upregulates AMPARs through an unknown mechanism. 67 Arc acts 
as a sensor of neural activity, augmenting endocytosis when activity is elevated. 
 Conversely, blocking neural activity increases Arc levels and the AMPAR surface 
population. Arc overexpression nullifies the gains in AMPARs that normally 
accompanies TTX-induced activity reduction, and Arc hippocampal cell culture 
knockouts exhibit no compensatory scaling in either direction. 68 This compensatory 
mechanism poses an obstacle for the development of sustainable drug therapy. 69 
Furthermore, any therapy must be precise enough to distinguish between constitutive and 
regulated AMPA trafficking. The activity-independent constitutive pathway, typically of 
GluA2/3 bearing receptors, maintains the total number of AMPARs and is thought to 
replace damaged receptors and preserve newly formed memories. The regulated pathway 
traffics predominantly GluA1-containing AMPARs, is inactive under basal conditions 
and is activated by LTP. 70 
 
Neuropathology 
 
 AMPARs are putatively involved in many diseases, including X-linked mental 
retardation, Alzheimer’s disease, amyotrophic lateral sclerosis, limbic encephalitis, 
epilepsy, ischemic brain injury, and Rasmussen’s encephalitis. 71, 72, 73, 74, 75 
 Given that Alzheimer’s dementia (AD) threatens to exacerbate the looming 
demographic-healthcare crisis, the role of AMPAR dysfunction in AD deserves special 
attention. An estimated 3.4 million people are affected by dementia in the United States. 
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76 The elderly population (aged over 65) is expected to double by 2030, reaching 72 
million, or 20% of the total U.S. population. 77 A similar shift awaits the developed world.  
 AD is characterized by the progressive loss of neural function, culminating in cell 
death and impaired cognition. The fundamental etiology of AD remains controversial, 
though there seem to be certain histological hallmarks including "-amyloid (A"42), 
neurofibriliary tangles composed of hyperphosphorylated tau, inflammation, oxidative 
stress, adrenergic and cholerinergic deficits. 78 79 A novel disease model even implicates 
insulin resistance – the “type 3 diabetes” hypothesis. 80  
 
 
Figure 9: Suspected Pathological Molecules in Alzheimer’s Dementia. A"42 can exist as intercellular 
monomers, inhibiting the proteasome, as well as in the more familiar form of intracellular plaques. 81 
 
 Whether A" or tau are by-products of another underlying mechanism, or whatever 
precise ratio of causal factors, AMPARs are intimately involved. A" secretion adversely 
affects LTP and depresses both AMPAR and NMDAR currents in cultured slices. 82, 83 
Furthermore, A" has proven capable of phosphorylating AMPARs at Ser880, signaling 
LTD and endocytosis, indicating that A" may be responsible for synaptic depression, 
AMPAR withdrawal, and dendritic spine loss. 84 The loss of spines and synaptic 
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sensitivity presages cognitive impairment, and safe, effective methods of preserving 
AMPAR function and neural integrity are certainly called for.  
 
Pharmacology 
 
Agonists 
 
 Each AMPAR has four glutamate binding sites, putatively formed by the 
extracellular N-tail and the extracellular loop between transmembrane domains three and 
four. The channel opens when two sites are bound, and as more sites are bound, more 
current flows through the ionopore. 85  
 Full agonists are almost exclusively used to induce lesions for ablation 
experiments. They include various AMPA analogues, williardiine analogues (found in 
Mimosa bark), 86 domoic acid (culprit in amnesic shellfish poisoning and algal bloom 
toxicity), 87 and quisqualic acid, an L-glutamic acid analogue found in Combretum 
indicum (traditionally used as an antihelmintic). These few compounds that have been 
characterized thus far are simply too potent for therapeutic use. (See Appendix for IC50 
values).  
 
Antagonists 
 
 Antagonists have demonstrated much more clinical relevance. One excessively 
well-characterized compound, ethanol, partially acts as an AMPAR antagonist. 88 
Upregulation of AMPARs in alcoholics is implicated in hyperactive excitation during the 
withdrawal period. 89 The drug acamprosate (N-acetyl homotaurine) acts as an antagonist 
at NMDARs and an agonist at GABAA receptors. The drug is of questionable efficacy, 90 
but future compounds may be more effective if they target AMPAR regulation as well. 91 
There is important emerging evidence for the involvement of AMPARs in addiction. 92, 93  
 Other antagonists include L-theanine (found at high levels in tea), a putative 
cognitive enhancer 94 and neuroprotective agent; 95 kynurenic acid, an endogenous 
tryptophan analogue implicated in schizophrenia 96 and cognitive impairment; 97 as well 
as the experimental receptor blockers CNQX and NBQX. There is also reason to believe 
that norepinephrine inhibits AMPAR currents in all layers of the rat temporal cortex. 98  
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 The AMPAR antagonists perampanel and tezampanel have found clinical 
application in the treatment of epilepsy and as neuroprotective agents after stroke, 
traumatic brain injury and the attendant excitotoxicity. 99 Furthermore, tezampanel 
demonstrates analgesic and anxiolytic activity in animals. 100 
 
 
 
 
  
 
Allosteric Modulators 
 
 Both positive and negative allosteric modulators (AMs) provide greater precision 
of control or “fine tuning” of potential therapies. These drugs are also more selective for 
receptor subtypes because they bind less conserved allosteric regions (rather than merely 
binding the glutamate site of the LBD or blocking the ion pore with varying affinities). 101 
 Furthermore, AMs are believed to impact receptor dynamics less, leading to 
reduced withdrawal and tolerance formation because these drugs work with pre-existing 
receptor populations. AMs generally work by modifying the time course of deactivation 
and/or desensitization. These drugs do, however, affect neurotrophin expression – a fact 
that even further augments excitement about therapeutic application. 102 
  Negative AMs (NAMs) have not been studied much, but they include 
extracellular protons (via a pH sensing region on the LBD), 103 neurosteroids (like 
sulfated pregnenolone analogues), 104 and unsaturated fatty acids like arachidonic acid. 105 
More research in this area is certainly warranted.  
 Positive AMs (PAMs) have been studied more extensively, and they work in at 
least two different ways: some slow the rate of desensitization following repeated ligand 
binding to the LBD, while others obstruct the exit of the agonist from the LBD.  
 There are presently three structural classes of PAM:  
 
Fig 10: Perampanel and tezampanel 
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1. Pyrrolidinone and related piperidine compounds (e.g., aniracetam and CX614).    
 
 
 
2. Benzothiadiazide compounds (e.g., cyclothiazide, diazoxide) 
 
        
 
 
3. Biarylpropylsulfonamide compounds (e.g., PEPA, LY404,187).  
 
 
 
 Detailed crystallographic descriptions of these ligand-receptor interactions are 
now being correlated with network circuitry and behavioral output. This literature is 
quickly evolving and beyond the scope of this thesis. 106  
 What began with the -racetam family has expanded to encompass a host of other, 
highly potent and selective compounds; for example, PEPA has one hundred times the 
potency of aniracetam at the AMPAR in vitro. 107 PAMs are promising therapeutics for 
dementia, major depression, ADHD, Parkinson’s, Huntington’s, ALS and other cognitive 
disorders. Ailments characterized by neuron loss may be particularly amenable to PAM 
treatment because several ampakines augment brain-derived neurotrophic factor (BDNF) 
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expression in disease models. 108, 109, 110  Thus far, however, clinical trials for dementia 
have been lackluster due to bioavailability and blood-brain barrier issues.  
 
Figure 11: Locations of ligand binding for both AMPA and kainate receptors. 111 
 
 The ampakine farampator demonstrated an acute effect on short-term memory in 
a preliminary clinical trial of healthy elderly. 112 One concern is that prolonged ampakine 
use could downregulate synaptic AMPARs via compensatory homeostatic scaling. 
Lauterborn et al found that continuous incubation of cultured hippocampal slices with 
CX614 rapidly multiplied BDNF mRNA (over 3–12 h) but this was followed by a decline 
to control values over the next 36 hours coupled with a comcomittant decline in 
AMPARs at the synapse. 113 This finding portends a “crash.” Lauterborn, Gall, Lynch et 
al addressed this concern, finding that CX614 can sustain increases in BDNF protein 
without AMPAR downregulation when moderate doses were administered for three hour 
intervals rather than continuous (24 hr) incubation of brain slices in the ampakine 
solution (see data in appendix). 114  
 Deadwyler et al. demonstrated dramatic sleep-deprivation alleviating cognitive 
effects of CX717 in non-human primates performing a delayed match-to-sample task. 
Not only was performance augmented for 30-36 hour sleep-deprived monkeys (to the 
point of removing impairment), but also CX717 significantly augmented performance of 
well-rested monkeys in a dose dependent manner. Positron emission tomography 
measures of regional cerebral metabolic rates for glucose (CMRglc) during the task 
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revealed that activity in the PFC, dorsal striatum, and medial temporal lobe (including 
hippocampus) was significantly enhanced by CX717. 115 As these data show, correct 
matches were highly significantly increased (P < 0.001), and latency of response was 
reduced by a similar magnitude.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Normally rested + vehicle vs. Normal + CX717 delayed match-to-
sample task. Animals treated with CX717 outperformed in both accuracy and 
latency parameters.  Sleep deprived animals administered CX717 outperformed 
even those that were normally rested on both parameters. (N = 11) 115 
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Figure 13: A) Dose-Response Data. CX717 is shown administered on consecutive sessions for nine 
monkeys over three dose ranges (0.3–0.5 mg/kg, 0.8–1.0 mg/kg, and 1.5 mg/kg, IV). Each CX717 session 
(C, arrows) was interspersed with a single normal vehicle (V) session. B) Monkeys were given 0.8 mg/kg 
of CX717 midway of their sessions. C) Overall mean dose-effect relationship of CX717 on normal alert 
DMS performance across monkeys (n = 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14: Glucose consumption PET scan. Brain Region 
Abbreviations: Dorsal Prefrontal Cortex, Dorsal Striatum, 
Thalamus, and Medial Temporal Lobe. 115 
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AMPAR Subunit Characterization 
 
 Different permutations of subunits of the heterotetrameric AMPAR determine its 
functional characteristics. There are efforts underway to develop antibodies that 
selectively tag these receptors with subunit specificity with the expectation that novel 
therapies will ultimately take advantage of differential subunit localization and activity in 
disease states.  
 GluA2 receptors have been relatively easy to characterize because they exhibit a 
signature inward rectifying current and are responsive to an array of polyamines and 
toxins. The other three subtypes exhibit more subtle pharmacological and 
electrophysiological signatures.  
 In Neuron, Lu et al in the lab of Roger Nicoll at UCSF published an innovative 
single-cell knockout method that has yielded much greater insight into the precise subunit 
composition at CA1-Shaffer pyramidal neuron synapses. 116 GluA4 is conspicuously 
absent from their data, because although it is found in the brain, it has much lower 
expression levels than the other three. 117 According to Lu et al, GluA4 does not play any 
role in the AMPAR-mediated transmission in CA1 pyramidal neurons.  
 
 
 
Figure 15: Dimer of dimer subunit ratios in rat Shaffer-CA1 pyramidal neuron synapses. GluA1/2 
tetramers predominate both at the synapse (80%) and extrasynaptically (>90%), whereas GluA2/3 tetramers 
compose only about 16% of synaptic AMPA receptors. 118 
 
 
 Subunit composition is no mere technical curiosity – it is a major mechanism by 
which the brain regulates its level of excitation. For example, RNA editing replaces a 
80% 
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glutamine with an arginine at the TMD 607 residue of GluA2. This change accounts for 
the calcium impermeability of GluA2 and its inwardly rectifying current properties 
(letting more current in than out). Transgenic mice with impaired Q/R editing exhibit 
epileptic seizures and die within two weeks after birth. 119, 120 Understanding this kind of 
subtle change may yield profound dividends in human therapy.  
 
Unaddressed Research Questions 
 
Although great strides have been made, there are many questions that remain to be 
answered with regard to AMPARs trafficking and cognition. Two prominent researchers 
in the field, Jason Shepherd at the Picower Institute for Learning and Memory at MIT and 
Richard Huganir at the Howard Hughes Medical Institute at Johns Hopkins, ask the 
following questions in their comprehensive review: 1 
 
“Many basic cell biological questions still remain to be addressed. What is 
the role of locally synthesized receptors, and how are local translation and 
mRNA trafficking regulated? How do receptors traffic in and out of the 
entangled complex of proteins in the PSD? When does lateral diffusion 
versus direct insertion/internalization occur at synapses?  
 
In addition, a huge challenge remains to elucidate the role of AMPAR 
trafficking in vivo, in terms of precise mechanisms, as well as determine 
the role that these processes play in synaptic plasticity and behavior.  
 
Information can be stored in the brain for years, yet AMPARs are highly 
dynamic and have a metabolic half-life of only a couple of days. Therefore, 
if AMPAR levels do determine synaptic strength, how can synaptic weights 
be maintained for weeks, months, or years? Moreover, how do individual 
synapses within a neuron know how many receptors it needs to maintain its 
potentiated or depressed state?” 
 
Research Question(s) 
 
 This experimental thesis set out to address the following questions: Does a newly 
developed monoclonal antibody bind to AMPA receptors with subunit specificity and 
under what conditions? If the antibody binds to the appropriate sites where AMPARs are 
putatively found, and does so for numerous subunit permutations, then the antibody likely 
demonstrates avidity for multiple AMPA receptor subtypes.  
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  The AMPAR 1/2/3 monoclonal antibody (mAb) functions as a sort of 
experimental control – one can compare, for example, a GluA1-specific mAB to the 
novel “pan-AMPA” (1/2/3) mAb. If, for whatever reason a researcher must visualize all 
of the predominant AMPAR subunits of the CNS, this mAb would also serve that 
purpose.  
 These questions were addressed using double-label immunohistochemistry, 
confocal laser scanning microscopy and electron microscopy. These studies were 
conducted in accordance with the methods of Morrison et al. 2005. 121  
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Methods and Materials 
 
Expression of GluA1 on a plasmid vector in transformed E. Coli.  
 
 GluA1 subunit with an N-terminally fused SUMO protein by the lab of Dr. 
Thomas Moran, Director Microbiology Department, Icahn School of Medicine at Mount 
Sinai. The entire GluR1 receptor subunit has a molecular weight of 106 kD (Milipore) to 
101 kD (PhosphoSitePlus). Listed below is a portion of the extracellular N-terminal 
domain putatively containing antigenic target portion of the GluR1, fused with a SUMO 
peptide in bold. The molecular weight of this 376 peptide subsequence after the SUMO 
protein has been cleaved is 43kD. Including the SUMO protein, it weighs 48 kD.  
 
MGSSHHHHHHSSGLVPRGSHMASMSDSEVNQEAKPEVKPEVKPETHINLKV
SDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDL
DMEDNDIIEAHREQIGGSNFPNNIQIGGLFPNQQSQEHAAFRFALSQLTEPPKLL
PQIDIVNISDSFEMTYRFCSQFSKGVYAIFGFYERRTVNMLTSFCGALHVCFITPSF
PVDTSNQFVLQLRPELQDALISIIDHYKWQKFVYIYDADRGLSVLQKVLDTAAEK
NWQVTAVNILTTTEEGYRMLFQDLEKKKERLVVVDCESERLNAILGQIIKLEKNG
IGYHYILANLGFMDIDLNKFKESGANVTGFQLVNYTDTIPAKIMQQWKNSDARD
HTRVDWKRPKYTSALTYDGVKVMAEAFQSLRRQRIDISRRGNAGDCLANPAVP
WGQGIDIQRALQQVRFEGLTGNVQFNEKGRRTNYTLHVIEMKHDGIRKIGYWNE
DDKFVPAATD 
 The clonal line of mAb producing B-cells was expanded with hybridoma 
technology in the lab of Dr. Thomas Moran. The avidity of the 5 µg/mL GluA mAb was 
verified using a Western blot by sodium dodecyl sulfate polyacrylamide gel 
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electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane and visualized 
with anti-mouse secondary antibody conjugated with I125.  
 
Transcardial Perfusion and Brain Acquisition 
 
 The brains of six adult Sprague-Dawley rats and one macaque monkey (Macaca 
fascicularis) were acquired by transcardial perfusion. The rats were were deeply 
anesthetized with a lethal dose of chloral hydrate (300 mg/kg) and the monkeys were 
deeply anesthetized with ketamine (25 mg/kg) and Nembutal (30 mg/kg). The animals 
were transcardially perfused with cold 1% paraformaldehyde in PBS, followed with cold 
4% paraformaldehyde and 0.125% glutaraldehyde in phosphate buffered solution (pH 
7.4).  
 All experiments were performed according to the NIH guidelines for research on 
vertebrate animals and the Institutional Animal Care and Use Committee (IACUC) at the 
Mount Sinai School of Medicine approved all protocols.  The brains were immediately 
postfixed in 4% paraformaldehyde for an additional 6 h at 48° C. The brains were then 
cut into 50 micron sections on a Vibratome and preserved in 1% sodium azide. The 
human brain was accessed via Dr. Patrick Hof’s research program. 
 
Immunohistochemistry 
 
 A subset of sections underwent antigen retrieval, a process that breaks aldehyde 
crosslinks and renders the target antigens more “visible” to the antibody. The sections 
were rinsed in 37 ° C 200 mL dH2O for 5 minutes followed by 6.5 minutes in 100 mL of 
0.2M HCl and 1 mL pepsin. This was followed by three washes in RT phosphate 
buffered solution.  
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 A blocking solution was used in order to reduce non-specific mAb binding. The 
solution was made up of 5% bovine serum albumin, 0.2% cold water fish skin gelatin, 
and 0.3% Triton-X100 permeabilizing agent in phosphate buffered solution. The same 
protocol was followed for the primary (polyclonal GluA2/3 or monoclonal GluA1/2/3) 
and secondary Ab (1:400 diluted anti-Mouse Alexa 488 and anti-Rabbit 555) double-
label incubations. The sections then were mounted on microscope slides, stained with 
Vectashield and DAPI, dried and cover-slipped.  
 
Confocal and Electron Microscopy 
 
 Immunofluorescence of anti-Mouse Alexa 488 and anti-Rabbit 555 secondary 
fluorophores were analyzed and imaged using a Zeiss LSM 410 inverted laser scanning 
confocal microscope equipped with a ArKr 488/568 laser and Zeiss Plan-Neofluar 
objectives (Zeiss, Oberkochen, Germany). A colocalization correlation was generated 
using built-in Zeiss analysis software.   
 Ultrastructural analysis was performed using a Hitachi 7000 (Tokyo, Japan) 
electron microscope. We used 10 nanometer immunogold-conjugated secondary 
antibodies (preparation credit to Rishi Puri). We also conducted a dilution series in order 
to determine the appropriate concentration for secondary antibody, using 2.5, 5, and 10 
µg/mL. All images were prepared using Adobe Photoshop 7. 
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Results 
 
Characterization of anti-GluA monoclonal antibody 
 
 
Fig 1. Western blot analysis demonstrated immunoreactivity to GluA subunits 1, 2 and 3, 
but not 4. The antigen binding motif region was recognized at approximately molecular 
weight 48 kD. The control lane was using mock-transfected E. coli lysate supernatant.  
 
Single Label Confocal Microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Non-antigen retrieved rat prefrontal cortex stained with monoclonal GluA1/2/3 
antibody. Roman numerals denote layers of the neocortex. Ab binding was nonspecific. 
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Figure 3. Non-antigen retrieved rat 
hippocampus and stained with 
monoclonal GluA1/2/3. On the right 
is a magnified image of CA1 and the 
dentate gyrus.  
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Figure 4. Human Prefrontal Cortex with antigen retrieval. The section was stained with 
DAPI and GluA1/2/3. The binding pattern is puntate, indicating greater specificity.  
 
 
 
 
 28 
 Double Label Confocal Microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Antigen retrieved human prefrontal cortex stain of DAPI, GluA1/2/3 and Post 
Synaptic Density-95. Yellow punctae denote the sum of GluA1/2/3 and PSD-95, 
indicating a high degree of colocalization at the postsynaptic density. 
 
 
 
 
 
Human Hippocampus  
GluA1/2/3 + PSD-95 
 
Monkey Hippocampus 
GluA1/2/3 + PSD-95 
Rat Hippocampus 
GluA1/2/3 + PSD-95 
 
Figure 6. Double labeling with GluA1/2/3 and PSD-95 in 
human, monkey and rat hippocampus. Yellow denotes 
colocalization.  
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DAPI GluA1/2/3 
Monoclonal 
GluA2/3 
Polyclonal 
! 
Figure 7. Double labeling of rat CA1 hippocampus with the GluA1/2/3 
monoclonal antibody colocalized with the polyclonal GluA2/3 antibody. 
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Figure 8. Colocalization plot of the monoclonal GluA1/2/3 and GluA2/3 showing 
moderate colocalization. Generated using Zeiss Zen built-in colocalization correlation 
function.  
 
 
 
Figure 9. Electron microscopy of non-human primate (macaque) hippocampus labeled 
with 10 nm immunogold spheres conjugated to GluA1/2/3, which was used at a 
concentration of 10 µg/mL. The antibody was successfully localized to the post synaptic 
density of the dentritic spines.  
Figure 10. Dilution series of 2.5, 5, and 10 µg/mL immunogold nanospheres 
conjugated to monoclonal GluA1/2/3 antibody. 
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Discussion 
 
 The novel monoclonal antibody binds to the ionotropic glutamatergic AMPA 
receptor subunits 1, 2, and 3. Confocal laser scanning microscopy showed that the 
antibody forms discrete punctae in the neuropil alone and when colocalized with PSD-95, 
validating expected synaptic presence. The electron microscopic studies display a precise 
localization of gold particles at the postsynaptic density synapse, likely in synthetic pools 
within spines as well as stabilized on the membrane. Antigen retrieval is strongly advised 
to augment antigen specificity. The fact that the antibody does not bind GluA4 is 
acceptable because this subunit does not appear to play any major role in AMPA receptor 
trafficking.  
 The antibody does not colocalize with the polyclonal GluA 2/3 to a convincing 
degree, this dysfunction may be due to time-dependent storage degradation of the 
GluR2/3 antibody. A follow-up experiment is currently underway.  
 The monoclonal antibody is functional, particularly with antigen retrieval, 
between 5 to 10 µg/mL, pending confirmation with more confocal and EM double-
labeling with different sized nanogold spheres. Upon further validation, this antibody will 
be ready for the market and use by neuroscientists all over the world. Hopefully this 
novel antibody will provide a higher degree of subunit-specific granularity for 
experimentalists and will expedite the development of therapies that attenuate epilepsy, 
dementia, amylotrophic lateral sclerosis and other neuropathologies associated with 
deranged AMPA receptor dynamics.  
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Appendix 
 
 
 
Appendix Figure 1 
 
Adapted From Lauterborn et al. 114 : “Spaced ampakine treatments sustain elevated BDNF protein content 
without down-regulating AMPAR expression.  
 
A) Hippocampal slices were treated with CX614 for varied intervals (1 – 6 hr) and harvested 24 h after 
treatment onset.  
 
B) Bar graphs show group mean ± S.E.M. in situ hybridization labeling densities for GluR1 mRNA in str. 
granulosum and CA1 str. pyramidale. With CX614 at 50 µM (light bars), labeling was unaffected through 3 
h but was lower than control values after 5 h treatments (*p < 0.05, **p < 0.01, ***p < 0.001 vs. con, SNK). 
CX614 at 25 µM (dark bars) did not affect GluR1 mRNA levels.  
 
C) Slices were treated with 50 µM CX614 for 3 h on four successive days; slices were collected daily (i) at 
the end of treatment for GluR1 mRNA analysis (D) or (ii) at the end of the 24 h period for ELISA measures 
of BDNF protein (E).  
 
D) Bar graph shows that GluR1 mRNA levels in str. granulosum (SG) remained at control values through 
treatment day 4 [at 50 µM] 
 
E) Plot of protein measures shows that total slice BDNF protein content was elevated at the end of the first 
day of treatment and remained elevated through treatment day 4 (**p < 0.01 vs. Con group) whereas GluR1 
protein levels were unchanged throughout treatment. Mean ± S.E.M. values shown for n ! 8/group.” 
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The following tables are adapted from Traynelis et al. 111 :  
  
 
 
 
 
 
 
 
 
 
 
 
 
Carboxyl-terminal protein binding partners for AMPAR subunits 
 
 
Post-Translational Modifications of C-terminal Domains of GluA 
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AMPAR Subunit Agonists at Micromolar Concentrations 
 
 
 
 
The Douglas Adams Equation and Secret to Universe Cube Matrix (Sum 3 x 3).  
(Congratulations for Finishing the Paper) 
 
 
 
 
 
 
 
 
 
 
 
